Research, News & Discoveries

Kavalali’s team identified spontaneous neurotransmission–dependent signaling mechanisms that help explain how certain antidepressants can act rapidly in the brain. Read More

In honor of the 2026 Women’s History Month, the Vanderbilt University School of Medicine Basic Sciences is highlighting female faculty from our school. We asked them to reflect on their journeys and the changes they have experienced in how biomedical research and academia treat their women. Read More

Meet Kirsty Erickson, a Ph.D. candidate in the lab of Cody Siciliano in the Department of Pharmacology. Read More

Recent work from the labs of Vivian Weiss and Ethan Lee shows a direct connection between exposure with PFAS—also known as “forever chemicals”—with changes in the morphology and function of thyroid tissue Read More

As Vanderbilt prepares for Giving Day, the Roger Chalkley, Ph.D. Critical Need Fund highlights the powerful impact that philanthropic support can have on trainees navigating the unpredictable realities of life during graduate school. Read More

Joyonna Gamble-George, PhD’16, believes that science is humanitarianism. Thanks to her upbringing and her Vanderbilt training, through the roles she has had—from entrepreneur to research scientist to policy fellow—she has focused on helping people in her personal and professional lives. Read More

Department of Cell and Developmental Biology faculty are unraveling the mysteries of human cells one discovery at a time. Read More

Meet Lisa Evans, senior program assistant in the Department of Biochemistry. Read More

Prashant Donthamsetti, assistant professor of pharmacology at the School of Medicine Basic Sciences, will deliver an upcoming Kairos Lecture on Thursday, March 26. Read More

A new study from the laboratory of Cody Siciliano suggests that two widely used medications for alcohol use disorder—naltrexone and nalmefene—may be equally effective overall but individuals only respond to one of the two medications. The findings could help explain why clinical trials of naltrexone and nalmefene have produced conflicting results and may point toward a precision-medicine strategy for treating alcohol use disorder. Read More